anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE: Provided is a make up composition especially of mascara for eyelash, containing polyolefin wax emulsified in the water. The amount of cosmetic content applied to the eyelashes is controlled easily. And it is easy to apply and comfortable to wear the cosmetic product. The polyolefin wax is compatible with any waxes used for existing mascara and can be mixed with them. CONSTITUTION: The emulsified composition for making up the keratin fiber such as hair or eyelashes contains one or more polyolefin wax produced from polymerization of alpha-olefin having 10 or more carbons. The melting point of the polyolefin wax is 50-80°C, the pointer penetration of the polyolefin wax measured at 44°C is 15-120, desirably 100-120, the number average molecular weight thereof is 400-3000, desirably 2000-3000 and its density is 0.85-0.95 g/cm.
INTRODUCTION: Obesity has been found to be correlated with numerous health issues, including an elevated risk of albuminuria in adults. However, this correlation is still controversial among children and adolescents, as several recent large-scale cross-sectional studies have observed a negative correlation between obesity and albuminuria. Our study aimed to investigate the link between the body roundness index (BRI) and albuminuria among children and adolescents, in order to further understand the correlation between obesity and albuminuria in this demographic.
METHODS: We employed information from the National Health and Nutrition Examination Survey (NHANES) 1999-2010 for cross-sectional analysis. Weighted logistic regression was employed to explore the linear relationship between BRI and albuminuria, with subgroup analyses performed for more detailed insights. Weighted linear regression analysis was employed to explore the relationship between BRI and the urine albumin-creatinine ratio (UACR). Additionally, we applied smooth curve fitting to investigate their non-linear relationship and conducted threshold effect analysis to identify any turning point.
RESULTS: In this study of 15,487 participants aged 8-19 years, multivariate logistic regression analysis revealed a significant negative correlation between BRI and albuminuria (OR = 0.616, 95%CI: 0.526-0.722). The relationship between BRI and UACR, as shown by multivariate linear regression analysis, was significantly inversely correlated (β: -5.424, 95%CI: -7.416 to -3.433). Furthermore, smooth curve fitting and threshold effect analysis showed a non-linear relationship between BRI and albuminuria, with a BRI inflection point identified at 2.906.
CONCLUSIONS: These findings of our study suggest a significant nonlinear negative association between BRI and the presence of albuminuria among children and teenagers, and maintaining an appropriate BRI may decrease the occurrence of albuminuria in this population.
The invention discloses a drug for treatment of rheumatic arthritis. The drug is characterized in that it is a granule, a tablet or a capsule made from the following raw material drugs by weight: 2-4 of masson pine bark, 1.5-2.5 of field thistle, 2.3-3.5 of white paeony roots, 2-4 of roots of sageretia theezans, 1.5-2.5 of honeysuckle, 2-4 of panax notoginseng, 1.5-2.5 of sodium bicarbonate, 2-4 of Rhizoma Heterosmilacis Japonicae, 1.5-2.5 of radix rehmanniae, and 1.5-2.5 of eleusine indica. The drug provided in the invention is used for treating rheumatic arthritis, and after taking it, a good curative effect can be achieved. The drug has the efficacy of joint swelling reducing, pain relieving, and joint function recovery and improvement, etc. Through preliminary clinical verification, the drug has a rheumatic arthritis cure rate up to 96.5% and an effective rate of 100%. In addition, the drug also has the characteristics of easily available medicinal raw materials, and convenient administration, etc.
In this study participants will receive the drug combination gemcitabine/carboplatin and bevacizumab once every two weeks. As long as there is evidence that the tumor is not growing and the participant is not experiencing any unacceptable side effects, participation can continue up to 2 years. The study is being done to find the effectiveness, safety and tolerability of this combination of chemotherapy drugs. Bevacizumab affects the growth of new blood vessels in the body. It is part of this study to see if stopping the growth of new blood vessels in the body will help stop the growth and the spread of cancer. The other two chemotherapy drugs, gemcitabine and carboplatin, are currently being used together for the treatment of ovarian cancer.
Participants will perform daily at-home subcutaneous placebo injections after receiving thorough at-home education training provided by a pharmaceutical nurse before and research personnel. Starting doses will be 0.2 ug/L and 0.3 ug/L for women taking exogenous oral estrogen.
PURPOSE:To make a cancer-related antibody which enables the measurement and the diagnosis of cancer cells such as those of digestive organs by identifying fucose antigen. CONSTITUTION:In the manufacture of a fucose antigen related to the titled antibody, oligosaccharide containing alpha-fucopyranosyl-(1 3)-,-(1 4)-or-(1 6)-galactopyranosyl group is used as hapten. Natural or synthetic high molecular protein ordinarily applied for the preparation of the antigen is used as a carrier protein connected to the oligosaccharide. The reaction between the oligosaccharide and the protein carrier is carried out by widely accepted various methods. This enables the manufacture of the desired saccharic antigen (fucose antigen). The antigen thus obtained is administered to a mammal and an antibody produced in an organism is sampled and refined to obtain the titled antibody.
AE data are obtained by the Investigators through observation of the Subject (including examinations and investigations), from any information volunteered by the Subject and through active questioning. At each visit after informed consent has been signed, Subjects will be asked about AEs that occurred since the last visit by questioning them with regard to their well-being by "non-leading" questions. This includes AEs occurring during the administration of IMP, as well as changes in concomitant diseases (e.g. ongoing medical history). The general type of questions could be similar to "Do you have any health problems?" or "Have you had any health problems since your last clinic visit?" During blinded studies, the Subject and all personnel involved with the conduct and interpretation of the study, including the Investigators, site personnel, and the Sponsor's staff, those involved in processing and regulatory reporting of SUSARs, will be blinded to the treatment codes until unblinding. The randomisation schedule will be filed securely by the Sponsor/IRS provider in a manner such that blinding is properly maintained throughout the study. Treatment codes will not be available until unblinding, after completion of the study and data base lock, except in the case of emergency.

Statistical analyses will be performed by a designated CRO. All statistical analyses will be performed using SAS and/or other statistical software as required.
Participants will receive a recombinant DNA plasmid vaccine placebo injection at study entry and on Days 28 and 56, followed by a recombinant adenoviral serotype vector vaccine placebo injection on Day 168. As of April 2013, all vaccinations in this study have been stopped.
In this group, 20 participants will be included. the interventions will be given for 15 mint. The exercises then repeated five or six times in a Session. the session will be of 45 mins, 3 session per week.
Patients will receive general anesthesia according to the standard general anesthesia protocol for this study. In addition, after induction of anesthesia, patients will begin receiving an intravenous infusion of lidocaine at a dose of 0.5 mg per kg per hour, and will continue to receive the infusion after surgery for a total of 24 hours.
The monocyte response from patients with T1D CKD will be compared to monocytes from T1D subjects without CKD as a control. Potential subjects will be recruited from existing Cleveland Clinic patients or the community. The study will entail an initial phone screen followed by a formal screening visit to determine eligibility. Eligible subjects will return for a study visit within 4 weeks for a blood draw. There is no intervention. This will complete the study for subjects unless the investigators do not obtain enough monocytes from the initial blood draw to complete the requisite lab studies. If this occurs, the investigators will ask the patient to return for a repeat study visit. All endpoints evaluating monocyte and podocyte injury will be conducted in the lab ex vivo.
Two 12-week, multicenter, randomized, double-blind studies compared continuous subcutaneous infusion of treprostinil injection to placebo in a total of 470 patients with NYHA Class II (11%), III (81%), or IV (7%) PAH. PAH was idiopathic/heritable in 58% of patients, associated with connective tissue diseases in 19%, and the result of congenital systemic-to-pulmonary shunts in 23%. The mean age was 45 (range 9 to 75 years). About 81% were female and 84% were Caucasian. Pulmonary hypertension had been diagnosed for a mean of 3.8 years. The primary endpoint of the studies was change in 6-minute walking distance, a standard measure of exercise capacity. There were many assessments of symptoms related to heart failure, but local discomfort and pain associated with treprostinil injection may have substantially unblinded those assessments. The 6-minute walking distance and an associated subjective measurement of shortness of breath during the walk (Borg dyspnea score) were administered by a person not participating in other aspects of the study. Treprostinil injection was administered as a subcutaneous infusion, described in Section 2, DOSAGE AND ADMINISTRATION, and the dose averaged 9.3 ng/kg/min at Week 12. Few subjects received doses greater than 40 ng/kg/min. Background therapy, determined by the investigators, could include anticoagulants, oral vasodilators, diuretics, digoxin, and oxygen, but not an endothelin receptor antagonist or epoprostenol. The two studies were identical in design and conducted simultaneously, and the results were analyzed both pooled and individually.

###  Hemodynamic Effects

As shown in Table 5, chronic therapy with treprostinil injection resulted in small hemodynamic changes consistent with pulmonary and systemic vasodilation.

* Denotes statistically significant difference between treprostinil injection and placebo, p<0.05.

CI = cardiac index; PAPm = mean pulmonary arterial pressure; PVRI = pulmonary vascular resistance indexed; RAPm = mean right atrial pressure; SAPm = mean systemic arterial pressure; SVRI = systemic vascular resistance indexed; SvO2 = mixed venous oxygen saturation; HR = heart rate.

###  Clinical Effects

The effect of treprostinil injection on 6-minute walk, the primary endpoint of the 12-week studies, was small and did not achieve conventional levels of statistical significance. For the combined populations, the median change from baseline on treprostinil injection was 10 meters and the median change from baseline on placebo was 0 meters from a baseline of approximately 345 meters. Although it was not the primary endpoint of the study, the Borg dyspnea score was significantly improved by treprostinil injection during the 6-minute walk, and treprostinil injection also had a significant effect, compared with placebo, on an assessment that combined walking distance with the Borg dyspnea score. Treprostinil injection also consistently improved indices of dyspnea, fatigue, and signs and symptoms of pulmonary hypertension, but these indices were difficult to interpret in the context of incomplete blinding to treatment assignment resulting from infusion site symptoms.
A veterinary composition for the treatment of infestations of nematodes in sheep and cattle by oral or parenteral administration comprises 100 parts by weight of one or more ammonium cations of the formula <FORM:0973231/A5-A6/1> wherein R1 is a hydrogen or halogen atom or a methyl, ethyl, methoxy, methyl-mercapto, formyl, acetyl, cyano, nitro or nitroso group, when M is a benzyl group optionally substituted in the ortho-position with a halogen atom or a methyl, ethyl, methoxy, methyl mercapto, nitro or nitroso group or R1 is a hydrogen or halogen atom or a methyl or nitro group when M is a thenyl group, in the form of one or more of their pharmaceutically acceptable salts and 0.05 to 25.0 parts by weight of one or more esters of formula <FORM:0973231/A5-A6/2> wherein R2 and R3 are the same or different and each is an alkyl group, X is oxygen or sulphur and R4 is hydrogen or halogen.  Preferably both R2 and R3 are ethyl. Specified esters are 3 - chloro - 4 - methyl - 7 - oxycoumarin - o,o - diethylphosphoric acid ester and the corresponding thiophosphoric acid ester, 4-methyl-7 - oxycoumarin - o,o - diethylphosphoric acid ester and 3-bromo-4-methyl-7-oxycoumarin-o,o-diethyl thiophosphoric acid ester.  Preferred salts of Formula I are the chloride, bromide, iodide, citrate, p-toluenesulphonate p - chlorobenzenesulphonate, 2 - hydroxy - 3, naphthoate and embonate.  The composition may be administered orally, as non-aqueous suspensions, powders, tablets, capsules, cachets, granules, animal feedstuffs, emulsions of the oil-in-water or water-in-oil type, syrups, drenches, coated tablets or granules, aqueous or oil suspensions and dispersible powders.  The compositions are formulated with diluents, anionic surface-active agents, dispersing agents, lubricants, flavours, thickeners, preservatives and binders.
Prospective pilot study, to be performed in 30 patients with Barrett's esophagus that have an indication for ablation treatment. Barrett's ablation will be performed using the EndoRotor®.
BACKGROUND: Presbycusis, also referred to as age-related hearing loss (ARHL), is a condition that results from the cumulative effects of aging on an individual's auditory capabilities. Given the limited understanding of epigenetic mechanisms in ARHL, our research focuses on alterations in chromatin-accessible regions.
METHODS: We employed assay for transposase-accessible chromatin with high-throughput sequencing (ATAC-seq) in conjunction with unique identifier (UID) mRNA-seq between young and aging cochleae, and conducted integrated analysis as well as motif/TF-gene prediction. Additionally, the essential role of super-enhancers (SEs) in the development of ARHL was identified by comparative analysis to previous research. Meanwhile, an ARHL mouse model and an aging mimic hair cell (HC) model were established with a comprehensive identification of senescence phenotypes to access the role of SEs in ARHL progression.
RESULTS: The control cochlear tissue exhibited greater chromatin accessibility than cochlear tissue affected by ARHL. Furthermore, the levels of histone 3 lysine 27 acetylation were significantly depressed in both aging cochlea and aging mimic HEI-OC1 cells, highlighting the essential role of SEs in the development of ARHL. The potential senescence-associated super-enhancers (SASEs) of ARHL were identified, most of which exhibited decreased chromatin accessibility. The majority of genes related to the SASEs showed obvious decreases in mRNA expression level in aging HCs and was noticeably altered following treatment with JQ1 (a commonly used SE inhibitor).
CONCLUSION: The chromatin accessibility in control cochlear tissue was higher than that in cochlear tissue affected by ARHL. Potential SEs involved in ARHL were identified, which might provide a basis for future therapeutics targeting SASEs related to ARHL.
Microspheres made of solid glass are used in radiation therapy, wherein the radiotherapeutic radionuclide must be generated in the glass by neutron activation. Microspheres of this type have a high radioactive load, are relatively heavy and contain additional non-therapeutic radionuclides. In addition, radioactive microspheres made of plastic are used, which can be loaded with radionuclides by chemical means. These microspheres have a lower loading capacity, no additional radionuclides, and are lighter. The therapeutic radionuclide in both cases is Y-90. Microspheres made of nanoporous glass contain the therapeutic radionuclide, have a high loading capacity, require no neutron activation, can be parallel charged with multiple therapeutic and also with diagnostic radionuclides, and are very light. It is possible to produce them in a radiochemical laboratory. Microspheres of this type can also be used diagnostically in preparation for therapy. For this purpose, they can be provided in a therapeutically or diagnostically specified quantity and radioactivity.
For the first exposure session, participants are exposed to filtered air (FA) for 6 hours. For the second exposure session, the same participant will be exposed to ozone at a concentration of 0.07ppm for 6 hours.
Inflammation is a key factor in both influenza and radiation-induced lung pathophysiology. This implies a commonality of response to pulmonary damage from these insults and suggests exacerbated pathology may occur after combined exposure. We therefore tested the hypothesis that past inflammation from viral infection alters the lung microenvironment and lowers tolerance for radiation injury. Mice were inoculated with influenza A virus (IAV) and three weeks later, after virus clearance, mice received total-body irradiation (TBI). Survival as well as systemic and local lung inflammation were assessed, and strategies to mitigate pulmonary injury were investigated. After IAV infection alone, body condition recovered within 3 weeks, however inflammatory pathways remained active for 15 weeks. IAV infection exacerbated subsequent TBI responses, evident by increased lethality, enhanced histologically evident lung injury and an altered lung macrophage phenotype. To mitigate this enhanced sensitivity, captopril [an angiotensin converting enzyme inhibitor (ACEi)] was administered to limit tissue inflammation, or inflammatory monocyte-derived macrophage recruitment was blocked with a C-C chemokine receptor type 2 (CCR2) inhibitor. Both treatments abrogated the changes in circulating immune cells observed 4 weeks after TBI, and attenuated pro-inflammatory phenotypes in lung alveolar macrophages, appearing to shift immune cell dynamics towards recovery. Histologically apparent lung injury was not improved by either treatment. We show that latent lung injury from viral infection exacerbates radiation morbidity and mortality. Although strategies that attenuate proinflammatory immune cell phenotypes can normalize macrophage dynamics, this does not fully mitigate lung injury. Recognizing that past viral infections can enhance lung radiosensitivity is of critical importance for patients receiving TBI, as it could increase the incidence of adverse outcomes.
Individually titrate OXAYDO to a dose that provides adequate analgesia and minimizes adverse reactions. Continually reevaluate patients receiving OXAYDO to assess the maintenance of pain control, signs and symptoms of opioid withdrawal, and other adverse reactions, as well as to reassess for the development of addiction, abuse, or misuse [see Warnings and Precautions (5.1, 5.14)]. Frequent communication is important among the prescriber, other members of the healthcare team, the patient, and the caregiver/family during periods of changing analgesic requirements, including initial titration.

If the level of pain increases after dosage stabilization, attempt to identify the source of increased pain before increasing the dosage of OXAYDO. If after increasing the dosage, unacceptable opioid-related adverse reactions are observed (including an increase in pain after a dosage increase), consider reducing the dosage [see Warnings and Precautions (5)]. Adjust the dosage to obtain an appropriate balance between management of pain and opioid-related adverse reactions.
In this study one CE-labeled Phonak Receiver-in-the-canal (RIC) devices is investigated. The experimental device will be investigated regarding Sound Quality perception ot the T-Coil program. A secondary objective of this study is the investigation of the Overall system stability in daily life situations. The experimental device contains direct connectivity functionality and a T-Coil. The combination of a wireless chip for Bluetooth streaming and a T-Coil in one housing can cause audible artifacts on the T-Coil, which shall be investigated within this study. This will be a clinical evaluation which will be conducted mono centric at Sonova AG Headquarters based in Stäfa (Switzerland).
Monocytopoiesis is a hematological process that supplies the periphery with monocytes and subsequently with macrophages and monocyte-derived dendritic cells. Typically, monocytes circulate in the bloodstream for a very short time before undergoing apoptosis, however, stimulatory signals can trigger monocyte survival by inhibiting the apoptotic pathway, and thus contribute to the maintenance of the inflammatory response. Accordingly, there is a need for methods and pharmaceutical compositions for modulating monocytopoiesis. Now, the inventors show that type I interferons signaling promote the differentiation of monocyte-derived phagocytes at the level of their progenitors. Importantly, IFN-alpha and -beta were found to efficiently generate the development of monocyte-derived antigen-presenting cells while having no impact on the precursor activity of conventional dendritic cells. Accordingly, modulators of type I interferon (e.g. neutralizing antibodies or type I IFN polypeptides) would be suitable for modulating monocytopoiesis in subjects in need thereof.
The subject receives Active Electric Stimulation Therapy for 12 weeks, 2 weeks after laparoscopic IPG and lead implant procedure. The subject and physician will be blinded to the randomization group assignment. The subject continues on stimulation treatment after 14 weeks and an extended open-label follow-up phase includes annual visits through 5 years.
Sitaglipin (MK-0431), 25 mg, once daily for 12 weeks, orally. Due to interim analysis of this study and another Phase IIB study, participants in this arm were switched into the 100-mg once daily arm during either the first or initiation of the second extensions study periods.
Training and consultancy services based on the teach-back method will be provided to individuals in the training group using the "Heart Failure Training Guide" in the form of 3 follow-ups in the cardiology clinic and telephone counseling. Telephone interviews were conducted by the researcher in the first week after discharge, it will be held in the first month and 3rd month. In addition, patients will receive counseling by calling the researcher if necessary.